Neuroimaging Characteristics of Patients with Chronic Schizophrenia and Predictive Diagnosis of Melatonin Therapy

Objective: To investigate the improvement of melatonin in cognitive function and safety of schizophrenia patients with tardive dyskinesia (TD). At the same time, the neuroimaging characteristics of patients with chronic schizophrenia were analyzed. Methods: 76 patients with chronic schizophrenia accompanied by TD were randomly divided into treatment group 39 cases and control group 37 cases. The treatment group was given melatonin 9 mg/d, while the control group was only treated with the original drug. The course of treatment is 12 weeks. Wechsler Adult Intelligence Scale (WAIS), Wechsler Memory Scale (WMS), Repeated Neuropsychological State Test (RBANS), Vocabulary Fluency Scale (VFT), and Symptom Scale (TESS) The curative effect and adverse reactions were evaluated before treatment and 12 weeks. Results: In the treatment group, WAIS was significantly higher than the control group in terms of semantic fluency and VFT in all indicators of operation, speech and total scale (P < 0.05 or P < 0.01); the differences in WMS indicators between the two groups were all different. No statistical significance (P > 0.05). The TESS score in the treatment group was significantly lower than before treatment (P < 0.05), and there was no significant difference between the two groups. Conclusion: Melatonin can improve the cognitive function of patients with chronic schizophrenia with TD, and it is safer.